Changes in connexin expression and the atrial fibrillation substrate in congestive heart failure

B Burstein, P Comtois, G Michael, K Nishida… - Circulation …, 2009 - Am Heart Assoc
B Burstein, P Comtois, G Michael, K Nishida, L Villeneuve, YH Yeh, S Nattel
Circulation research, 2009Am Heart Assoc
Rationale: Although connexin changes are important for the ventricular arrhythmic substrate
in congestive heart failure (CHF), connexin alterations during CHF-related atrial
arrhythmogenic remodeling have received limited attention. Objective: To analyze connexin
changes and their potential contribution to the atrial fibrillation (AF) substrate during the
development and reversal of CHF. Methods and Results: Three groups of dogs were
studied: CHF induced by 2-week ventricular tachypacing (240 bpm, n= 15); CHF dogs …
Rationale: Although connexin changes are important for the ventricular arrhythmic substrate in congestive heart failure (CHF), connexin alterations during CHF-related atrial arrhythmogenic remodeling have received limited attention.
Objective: To analyze connexin changes and their potential contribution to the atrial fibrillation (AF) substrate during the development and reversal of CHF.
Methods and Results: Three groups of dogs were studied: CHF induced by 2-week ventricular tachypacing (240 bpm, n=15); CHF dogs allowed a 4-week nonpaced recovery interval after 2-week tachypacing (n=16); and nonpaced sham controls (n=19). Left ventricular (LV) end-diastolic pressure and atrial refractory periods increased with CHF and normalized on CHF recovery. CHF caused abnormalities in atrial conduction indexes and increased the duration of burst pacing-induced AF (DAF, from 22±7 seconds in control to 1100±171 seconds, P<0.001). CHF did not significantly alter overall atrial connexin (Cx)40 and Cx43 mRNA and protein expression levels, but produced Cx43 dephosphorylation, increased Cx40/Cx43 protein expression ratio and caused Cx43 redistribution toward transverse cell-boundaries. All of the connexin-alterations reversed on CHF recovery, but CHF-induced conduction abnormalities and increased DAF (884±220 seconds, P<0.001 versus control) remained. The atrial fibrous tissue content increased from 3.6±0.7% in control to 14.7±1.5% and 13.3±2.3% in CHF and CHF recovery, respectively (both P<0.01 versus control), with transversely running zones of fibrosis physically separating longitudinally directed muscle bundles. In an ionically based action potential/tissue model, fibrosis was able to account for conduction abnormalities associated with CHF and recovery.
Conclusions: CHF causes atrial connexin changes, but these are not essential for CHF-related conduction disturbances and AF promotion, which are rather related primarily to fibrotic interruption of muscle bundle continuity.
Am Heart Assoc